Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions
AKRO Stock Forecast
Akero Therapeutics stock forecast is as follows: an average price target of $46.00 (represents a 50.13% upside from AKRO’s last price of $30.64) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
AKRO Price Target
AKRO Analyst Ratings
Buy
Akero Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 17, 2024 | Ed Arce | H.C. Wainwright | $50.00 | $26.97 | 85.39% | 63.19% |
Jun 12, 2024 | Edward Nash | Canaccord Genuity | $56.00 | $23.43 | 139.01% | 82.77% |
Jun 10, 2024 | Andy Chen | Wolfe Research | $40.00 | $22.99 | 73.99% | 30.55% |
May 15, 2024 | Liisa Bayko | Evercore ISI | $38.00 | $20.30 | 87.19% | 24.02% |
Oct 11, 2023 | Ed Arce | H.C. Wainwright | $40.00 | $15.04 | 165.96% | 30.55% |
Sep 13, 2022 | Liisa Bayko | Evercore ISI | $50.00 | $29.05 | 72.12% | 63.19% |
10
Akero Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 4 |
Avg Price Target | - | $50.00 | $46.00 |
Last Closing Price | $30.64 | $30.64 | $30.64 |
Upside/Downside | -100.00% | 63.19% | 50.13% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 18, 2024 | Citigroup | - | Buy | Initialise |
Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 12, 2024 | Canaccord Genuity | Buy | Buy | Hold |
Jun 10, 2024 | Wolfe Research | - | Outperform | Initialise |
May 15, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Sep 14, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
10
Akero Therapeutics Financial Forecast
Akero Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Akero Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Akero Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-87.50M | $-84.70M | $-77.65M | $-78.02M | $-80.74M | $-61.02M | $-57.38M |
High Forecast | $-87.50M | $-84.70M | $-77.65M | $-76.70M | $-77.20M | $-61.02M | $-57.38M |
Low Forecast | $-87.50M | $-84.70M | $-77.65M | $-79.34M | $-84.28M | $-61.02M | $-57.38M |
Surprise % | - | - | - | - | - | - | - |
Forecast
Akero Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Akero Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-1.26 | $-1.22 | $-1.12 | $-1.12 | $-1.16 | $-0.88 | $-0.83 |
High Forecast | $-1.26 | $-1.22 | $-1.12 | $-1.10 | $-1.11 | $-0.88 | $-0.83 |
Low Forecast | $-1.26 | $-1.22 | $-1.12 | $-1.14 | $-1.21 | $-0.88 | $-0.83 |
Surprise % | - | - | - | - | - | - | - |
Forecast
Akero Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.51 | $6.00 | 1076.47% | Buy |
BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
VKTX | Viking Therapeutics | $51.53 | $102.40 | 98.72% | Buy |
AKRO | Akero Therapeutics | $30.64 | $46.00 | 50.13% | Buy |
RNA | Avidity Biosciences | $43.65 | $54.50 | 24.86% | Buy |
PTGX | Protagonist Therapeutics | $40.65 | $50.00 | 23.00% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
MDGL | Madrigal Pharmaceuticals | $317.09 | $315.75 | -0.42% | Buy |